2019

Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death Dis.

Borkowetz A, Froehner M, Rauner M, Conrad S, Erdmann K, Mayr T, Datta K, Hofbauer LC, Baretton GB, Wirth M, Fuessel S, Toma M, Muders MH. Neuropilin‐2 is an independent prognostic factor for shorter cancer‐specific survival in patients with acinar adenocarcinoma of the prostate. International Journal of Cancer

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.   TRIM24 as an independent prognostic biomarker for prostate cancer. Urologic Oncology

Digomann D, Linge A, Dubrovska A. SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. Autophagy

Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer Stem Cells and radioresistance: DNA Repair and Beyond. Cancers (Basel)

Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J Cancer

Gorodetska I, Lukiyanchuk V, Peitzsch C, Kozeretska I, Dubrovska A. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. Int J Cancer

Peitzsch C, Kurth I, Ebert N, Dubrovska A, Baumann M. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int J Radiat Biol

Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle AA, Hein L, Kunz-Schughart LA, Abdollahi, A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A. The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clin Cancer Res

Peitzsch C, Nathansen J, Schniewind SI, Schwarz F, Dubrovska A. Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications. Cancers (Basel)

Hannemann N, Cao S, Eriksson D, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Rech J, Ramming A, Uebe S, Ekici A, Cañete JD, Chen X, Bäuerle T, Vera J, Bogdan C, Schett G, Bozec A. Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. J Clin Invest

Ellmann S, Seyler L, Evers J, Heinen H, Bozec A, Prante O, Kuwert T, Uder M, Bäuerle T. Prediction of early metastatic disease in experimental breast cancer bone metastasis by combining PET/CT and MRI parameters to a Model-Averaged Neural Network. Bone

Steffen U, Schett G, Bozec A. How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis. Front Immunol

Göbel A, Kuhlmann JD, Link T, Wimberger P, Link-Rachner C, Thiele S, Dell’Endice S, Furesi G, Breining D, Rauner M, Hofbauer LC, Rachner TD. Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. J Bone Oncol

Durst FC, Grujovic A, Ganser I, Hoffmann M, Ugocsai P, Klein CA, Czyż ZT. Targeted transcript quantification in single disseminated cancer cells after whole transcriptome amplification. PLoS One

Puppo M, Taipaleenmäki H, Hesse E, Clézardin P. Non-coding RNAs in Bone Remodelling and Bone Metastasis: Mechanisms of Action and Translational Relevance. Br J Pharmacol

Hesse E, Taipaleenmäki H. MicroRNAs in Bone Metastasis. Curr Osteoporos Rep

Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, Taipaleenmäki H, Hesse E. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nat Commun

Keller L, Werner S, Pantel K. Biology and clinical relevance of EpCAM. Cell Stress

Werner S, Keller L, Pantel K. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Molecular Aspects of Medicine

Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer

Münsterberg J & Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Robador Arteta JR, Bauer A, Wrage M, Lamszus K, Matschke J, Vashist Y, Uzunoglu G, Steurer S, Horst AK, Olivera-Ferrer L, Glatzel M, Schinke T, Corbeil D, Pantel K, Maire C, Wikman H. Upregulation of ALCAM is a marker for non-small-cell lung cancer brain metastases. Neuro-Oncology

Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nat Rev Clin Oncol

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S. TRIM24 as an independent prognostic biomarker for prostate cancer. Urol Oncol

2018

Engelmann J, Ben Batalla I, Taipaleenmäki H, Riecken K, Gensch V, Paesler S, Berenbrok N, Vargas ME, Waizenegger J, Fehse B, Pantel K, Darwish IS, Bhamidipati S, Masuda E, Bokemeyer C, Hesse E, Loges S. Blockade of Mer by the small molecule inhibitor R992 inhibits multiple myeloma and its associated bone disease by restoring the perturbed bone homeostasis. Blood